Shots:

• The acquisition expands SparingVision’s ocular genomic medicine pipeline with the addition of GAMUT’s lead product SPVN20- which is a novel- mutation-agnostic gene therapy- focuses on restoring the function of dormant cone cells in the retina. The acquisition is expected to close in Q2’21
• SparingVision plans to evaluate the therapeutic synergy with a combination of both products (SPVN06 and SPVN20) addressing both mid & late stages of rod-cone dystrophies in patients with RP
• Additionally- SparingVision will explore SPVN20 in other retinal diseases and has the right to participate in the creation of a new GIRK-based cell therapy company

  Ref: Globe Newswire | Image: Twitter